FDA Approves Scholar Rock's Isembyld, First Muscle-Targeted SMA Therapy — Muscular Dystrophy Association, Inc.

Event summary

FDA approved Isembyld (apitegromab-mstn) on September 11, 2026, as the first muscle-targeted therapy for SMA patients already on SMN2-targeted treatments.
The approval follows positive Phase 3 SAPPHIRE study results, showing clinically meaningful improvements in motor function.
MDA has invested over $50 million in SMA research, contributing to more than 30 FDA-approved neuromuscular disease treatments in the last decade.
Isembyld is a monthly infusion treatment designed to improve muscle function in SMA patients.
Scholar Rock will host industry update webinars for families (October 6, 2026) and clinicians (October 7, 2026).

The big picture

The approval marks a strategic shift in SMA treatment from merely slowing progression to actively improving muscle function. MDA's long-term research investment underscores the organization's role in driving neuromuscular disease innovation. With over $1.2 billion invested in research, MDA continues to shape the therapeutic landscape for rare genetic conditions.

What we're watching

Commercialization Strategy: How Scholar Rock will position Isembyld alongside existing SMN-targeted therapies in the competitive SMA treatment landscape.
Clinical Efficacy: Whether the motor function improvements seen in trials will translate to long-term benefits for nonambulatory SMA patients.
Market Expansion: The pace at which Isembyld could gain approval in international markets, given SMA's global prevalence.